Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow
Brachytherapy · 2024
DOI: 10.1016/j.brachy.2024.08.255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von J V Panetta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: Joseph.panetta@fccc.edu. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms, Workflow, Radiotherapy Planning, Computer-Assisted. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: High dose rate brachytherapy (HDR-BT) has been shown to be an effective treatment for prostate cancer, with treatment plan quality dependent on a number of factors. In this work, we report on the overall performance of our ultrasound (US)-based workflow and the impact of several treatment-specific variables. METHODS AND MATERIALS: Patients who underwent HDR-BT (boost, monotherapy, and retreatment) using Varian Bravos/US from 2021 to 2023 were sampled for this study. Treatment plan quality was analyzed and plans were categorized with regard to a number of metrics, including: prostate volume, treating physician, planning physicist, number of needles included, estimated planning time, rectum-prostate separation, and bladder-prostate separation. The performance of this program was compared to the performance of our program using previously used modality combinations: Varian Varisource/US, Elekta microSelectron/CT. RESULTS: Plan quality for our Bravos/US workflow was shown to be consistently above acceptability criteria for all personnel involved; on average: prostate V100%: 98.9% ± 0.1%, rectum V75%: 0.04 ± 0.01 cc, bladder V75%: 0.06 ± 0.01cc, urethra V125%: 0.00 ± 0.00 cc. Prostate coverage was statistically improved with this workflow compared to that using our previous modalities. There was a statistical correlation between organ-at-risk sparing/prostate coverage ratio and prostate volume, number of needles/prostate volume, bladder-prostate separation, and rectum-prostate separation. There was no correlation between plan quality and planning time. CONCLUSIONS: Our US-based HDR-BT program led to target coverage and organ-at-risk sparing that exceeded department thresholds. Results were acceptable regardless of the personnel involved and improved plan quality was obtained using more needles/prostate volume and increased spacing between the prostate and the rectum and bladder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: Joseph.panetta@fccc.edu.
- Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Panetta, J. V., Veltchev, I., Horwitz, E., Hallman, M., Wong, K., Price, R. A., & Ma, C. M. C. (2024). Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.08.255
Vancouver
Panetta JV, Veltchev I, Horwitz E, Hallman M, Wong K, Price RA, et al. Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow. Brachytherapy. 2024. doi:10.1016/j.brachy.2024.08.255
BibTeX
@article{Panetta2024,
author = {Panetta, J V and Veltchev, I and Horwitz, E and Hallman, M and Wong, K and Price, R A and Ma, C M C},
title = {Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow},
journal = {Brachytherapy},
year = {2024},
doi = {10.1016/j.brachy.2024.08.255}
}
EUVIMED